摘要
贝伐珠单抗抗血管生成疗法在晚期结直肠癌(mCRC)患者治疗中能够发挥重要作用,有利于提升生存率。对贝伐珠单抗抗血管生成疗法的临床标志物进行研究,有利于预测mCRC患者对贝伐珠单抗抗血管生成疗法的反应。本文主要对贝伐珠单抗抗血管生成疗法的临床标志物研究现状进行综述。
Anti-angiogenesis therapy with Bevacizumab plays an important role in the treatment of metastatic colorectal cancer(mCRC),which is beneficial to improve the survival rate.The study on clinical markers of anti-angiogenesis therapy with Bevacizumab is of great significance in predicting the response of antiangiogenesis therapy with Bevacizumab.In this paper,the status of clinical markers of anti-angiogenesis therapy with Bevacizumab is reviewed.
作者
沈新伟
薛大伟
邢丽
谢建军
SHEN Xinwei;XUE Dawei;XING Li;XIE Jianjun(Yanjiao People’s Hospital of Sanhe,Sanhe 065201,China;不详)
出处
《中外医学研究》
2020年第6期177-179,共3页
CHINESE AND FOREIGN MEDICAL RESEARCH
基金
2019河北省廊坊市科技支撑计划项目(项目编号:2019013052)。
关键词
贝伐珠单抗
晚期结直肠癌
临床标志物
Bevacizumab
Metastatic colorectal cancer
Clinical markers
